No Detail Found!

Risk factors for macro vascular disease in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease

Author(s)
Yunna Zhang Department of Second Endocrinology, Cangzhou Central Hosipital,Cangzhou, Hebei Province,China
Linxia Wang Department of Second Endocrinology, Cangzhou Central Hosipital,Cangzhou, Hebei Province,China
Xue Zheng Department of Third Ultrasonics, Cangzhou Central Hosipital,Cangzhou, Hebei Province,China
Hailun Wang Office of Hospital Infection Management, Cangzhou Central Hosipital,Cangzhou, Hebei Province,China
Guijiang Wang Department of Fourth Orthopedics, Cangzhou Central Hospital,Cangzhou, Hebei Province,China
Abstract
This study investigates the connection between abnormal liver enzymes and macro vascular disease in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD). Clinical data from 276 T2DM patients with NAFLD were retrospectively examined and divided into two groups based on the presence or absence of macro vascular disease. Various biochemical markers were tested, including fasting C-peptide, total bilirubin (TBil), total protein (TP), albumin (Alb), C-reactive protein (CRP) and the insulin resistance index (HOMA-IR). The study found no significant differences in demographic variables between the two groups. However, patients with macro vascular disease had significantly higher levels of fasting C-peptide, CRP, HOMA-IR, TBil, TP, Alb and certain blood lipid markers. The study concludes that in T2DM patients with NAFLD, increased blood lipids, liver function and inflammatory factors are risk factors for macro vascular disease, suggesting the importance of clinical management to lower macro vascular disease prevalence.
Publication Details
Page(s) 1297-1303
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 36, Issue: S4, Year: 2023

Request the full text from PASTIC

Keywords
type 2 diabetes, macro vascular disease, abnormal liver enzymes, non-alcoholic fatty liver
References
Ahmad E,Lim S,Lamptey R,Webb DR,Davies MJ DR .2022 .Type 2 diabetes. , 400(10365) : 1803-1820.
Artasensi A,Pedretti A,Vistoli G,Fumagalli L G .1987 .Type 2 Diabetes mellitus: A review of multitarget drugs. Molecules, 25(8) : .
Aryan Z,Ghajar A,Faghihi-Kashani S,Afarideh M,Nakhjavani M,Esteghamati A .2018 .Baseline high-sensitivity c-reactive protein predicts macrovascular and microvascular complications of Type 2 diabetes: A population-based study. Ann. Nutr, 72(4) : 287-295.
Atkinson MA,Campbell-Thompson M,Kusmartseva I,Kaestner KH .2020 .Organisation of the human pancreas in health and in diabetes. Diabetologia., 63(10) : 1966-1973.
Bahreynian M,Qorbani M,Motlagh ME,Heshmat R,Khademian M,Kelishadi R M .2018 .Association of serum 25-hydroxyvitamin D levels and liver enzymes in a nationally representative sample of iranian adolescents: The childhood and adolescence surveillance and prevention of adult noncommunicable disease study. Int. J. Prev. Med, 9(24) : 24.
Bellary S,Kyrou I,Brown JE,Bailey CJ .2021 .Type 2 diabetes mellitus in older adults: Clinical considerations and management. Nat. Rev. Endocrinol., 17(9) : 534-548.
Caussy C,Aubin A,Loomba R .2021 .The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr. Diab. Rep, 21(5) : 15.
Chan CB,Harper ME .2006 .Uncoupling proteins: role in insulin resistance and insulin insufficiency. Curr. Diabetes. Rev., 2(3) : 271-283.
Cheng C,Deng X,Xu K X .2018 .Increased expression of sterol regulatory element binding protein-2 alleviates autophagic dysfunction in NAFLD. Int. J. Mol. Med, 41(4) : 1877-1886.
Chong PL,Laight D,Aspinall RJ,Higginson A,Cummings MH .2021 .A randomised placebo controlled trial of VSL#3(®) probiotic on biomarkers of cardiovascular risk and liver injury in nonalcoholic fatty liver disease. BMC Gastroenterol, 21(1) : 144.
JB. Florez Cole,JC Cole .2020 .Genetics of diabetes mellitus and diabetes complications. Nat. Rev. Nephrol., 16(7) : 377-390.
Dai W,Ye L,Liu A,Wen SW,Deng J,Wu X,Lai Z X .2017 .Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A metaanalysis. Medicine (Baltimore), 96(39) : e8179.
Ferguson D,Finck BN D .2021 .Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat. Rev. Endocrinol., 17(8) : 484-495.
Francisco V,Pino J,González-Gay M,Lago F,Karppinen J,Tervonen O,Mobasheri A,Gualillo O .2022 .A new immunometabolic perspective of intervertebral disc degeneration. Nat. Rev. Rheumatol., 18(1) : 47-60.
Fu R,Li J,Yu H,Zhang Y,Martin Z,C Z .2021 .The Yin and Yang of traditional Chinese and Western medicine. Med. Res. Rev., 41(6) : 3182-3200.
Garg K,Brackett S,Hirsch IB,Garg SK .2020 .NAFLD/NASH and Diabetes. Diabetes Technol. Ther., 22(S1) : S174-s186.
Golabi P,Stepanova M,Pham HT,Cable R,Rafiq N,Bush H,Gogoll T,Younossi ZM .2018 .Nonalcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). BMJ Open Gastroenterol. , 5(1) : e000198.
Guo D,Xiao L,Hu H,Liu M,Yang L,Lin X .2018 .FGF21 protects human umbilical vein endothelial cells against high glucose-induced apoptosis via PI3K/Akt/Fox3a signaling pathway. J. Diabetes Complicat., 32(8) : 729-736.
Javed Z,Papageorgiou M,Deshmukh H,Kilpatrick ES,Mann V,Corless L,Abouda G,Rigby AS,Atkin SL,Sathyapalan T .2019 .A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome. Nutrients, 11(1) : 188.
Lin Z,Yang F,Sun L,Gao J,Cao Y,Qiu H,Zhan X H .2018 .Systematically analyses of the common dysregulated networks to understand the common pathologies between T2D and atherosclerosis. Gene, 671(5) : 110-116.
Liu FS,Li Y,Guo XS,Liu RC,Zhang HY,Li Z HY .2022 .Advances in traditional Chinese medicine as adjuvant therapy for diabetic foot. World J. Diabetes, 13(10) : 851-860.
Liu XJ,Hu XK,Yang H,Gui LM,Cai ZX,Qi MS,Dai CM .2022 .A review of traditional Chinese medicine on treatment of diabetic nephropathy and the involved mechanisms. Am. J. Chin. Med, 50(7) : 1739-1779.
Liu Y,Zhang Y,Zhang K,Wang Y .2018 .Protocatechuic acid reduces H2O2-induced migration and oxidative stress of fibroblast-like synoviocytes in rheumatoid arthritis by activating Nrf2-Keap1 signaling pathway. World J. Tradit. Chin. Med, 4(1) : 28-35.
Nauck MA,Wefers J,Meier JJ .2021 .Treatment of type 2 diabetes: Challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol., 9(8) : 525-544.
Peng H,Wang S,Wang M,Ye Y,Xue E,Chen X,Wang X,Fan M,Gao W,Qin X,Wu Y,Chen D,Li J,Hu Y,Wang L,Wu T .2022 .Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study. Metabolism, 133 : 155220.
Powell EE,Wong VW,Rinella M .2021 .Nonalcoholic fatty liver disease. Lancet, 397(10290) : 2212-2224.
Stefan N and Cusi K .2022 .A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol., 10(4) : 284-296.
Targher G,Byrne CD,Tilg H CD .2020 .NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications. , 69(9) : 1691-1705.
Targher G,Corey KE,Byrne CD,Roden M .2021 .The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat. Rev. Gastroenterol. Hepatol., 18(9) : 599-612.
Tilg H,Adolph TE,Dudek M,Knolle P .2021 .Non-alcoholic fatty liver disease: The interplay between metabolism, microbes and immunity. Nat. Metab, 3(12) : 1596-1607.
Tinajero MG,Malik VS .2021 .An update on the epidemiology of type 2 diabetes: A global perspective. Endocrinol. Metab. Clin. North Am., 50(3) : 337-355.
Viigimaa M,Sachinidis A,Toumpourleka M,Koutsampasopoulos K,Alliksoo S,Titma T .2020 .Macrovascular complications of type 2 diabetes mellitus. Curr. Vasc. Pharmacol., 18(2) : 110-116.
Vural H,Armutcu F,Akyol O,Weiskirchen R O .2021 .The potential pathophysiological role of altered lipid metabolism and electronegative lowdensity lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases. Clin. Chim. Acta., 523(5) : 374-379.
Wang N,Wang Y,Zhang W,Chen Y,Chen X,Wang C,Li Q,Chen C,Jiang B,Lu Y .2020 .C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes. Diabetes Metab Res Rev., 36(2) : e3210.
Wu D,Wu C,Zhong Y C .2018 .The association between paraoxonase 1 activity and the susceptibilities of diabetes mellitus, diabetic macroangiopathy and diabetic microangiopathy. J. Cell. Mol. Med, 22(9) : 4283-4291.
Wu WKK,Zhang L,Chan MTV .2018 .Autophagy, NAFLD and NAFLD-related HCC. Adv. Exp. Med, 1061(2) : 127-138.
Yun JS,Ko SH .2021 .Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. , 123(11) : 154838.
0

Citations

0

Downloads

43

Views